We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current PCRX market cap is 1.31B. The company's latest EPS is USD 0.9022 and P/E is 31.18.
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 160.34M | 173.97M | 160.57M | 183.52M | 170.92M |
| Operating Income | -3.09M | 39.88M | 17.72M | 33.17M | 13.21M |
| Net Income | -19.54M | 25.76M | 10.86M | 24.87M | 8.98M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 421.03M | 429.65M | 541.53M | 666.82M | 678.4M |
| Operating Income | 10.48M | 46.35M | 89.92M | 60.02M | 87.68M |
| Net Income | -11.02M | 145.52M | 41.98M | 15.91M | 41.96M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 1.52B | 1.54B | 1.53B | 1.57B | 1.58B |
| Total Liabilities | 755.38M | 734.41M | 702.91M | 704.26M | 691.16M |
| Total Equity | 768.04M | 807.98M | 831.55M | 870.13M | 892.16M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 831.07M | 1.27B | 2.08B | 1.68B | 1.57B |
| Total Liabilities | 476.12M | 654.83M | 1.34B | 906.19M | 704.26M |
| Total Equity | 354.94M | 619.69M | 730.41M | 775.01M | 870.13M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 19.13M | 62.63M | 107.07M | 154.65M | 49.1M |
| Investing | 66.18M | 73.51M | 69.17M | 77.54M | -15.53M |
| Financing | -153.91M | -153.47M | -181.25M | -183.03M | -2.82M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 70.52M | 77.03M | 125.72M | 145.27M | 154.65M |
| Investing | -128.49M | -277.61M | -20.79M | -225.19M | 77.54M |
| Financing | 3.67M | 222.3M | 380.69M | -401.53M | -183.03M |
| Market Cap | 1.31B |
| Price to Earnings Ratio | 31.18 |
| Price to Sales Ratio | 1.93 |
| Price to Cash Ratio | 8.53 |
| Price to Book Ratio | 1.5 |
| Dividend Yield | - |
| Shares Outstanding | 46.5M |
| Average Volume (1 week) | 682.35k |
| Average Volume (1 Month) | 599k |
| 52 Week Change | -24.03% |
| 52 Week High | 41.65 |
| 52 Week Low | 25.33 |
| Spread (Intraday) | 1.5 (5.19%) |
| Company Name | Pacira BioSciences Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.pacira.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
